NICE TA450: for previously treated Philadelphia-Chromosome-negative acute lymphoblastic leukaemia. (NHSE commissioned). (Decision date - July 2017).
NICE TA589: - for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity. (NHSE commissioned). (Decision date - August 2019)
NICE TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (decision date April 2025)
DO NOT PRESCRIBE (DNP):
NICE TA686: for previously treated Philadelphia-Chromosome-positive acute lymphoblastic leukaemia. (Terminated appraisal). (Decision date - July 2017).
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
